Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 7:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 26,642 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Hypercatabolic Status Related to Severe Burn
Interventions: BVS857, placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Gynecologic Cancers
Interventions: Starting the Conversation, Sexual Health Resources; Behavioral
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Kidney Disease
Interventions: Zemplar Capsule; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 16
States / cities: San Diego, California • Washington D.C., District of Columbia • Fort Meyers, Florida + 12 more

Conditions: Osteo Arthritis Knee
Interventions: Geniculate Artery Embolization, Sham Procedure; Device · Diagnostic Test
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 40 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Woodbridge, Virginia

Conditions: Insomnia, HIV, Aids
Interventions: CBT-I Treatment Condition, SH Comparison Condition; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Diabetes Mellitus, Type 2
Interventions: BI 10773, Glimepiride, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,549 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 25
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • Sacramento, California + 20 more

Conditions: PostTraumatic Stress Disorder
Interventions: Ropivacaine, Sham treatment; Drug
Lead sponsor: RTI International; Other
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Honolulu, Hawaii • Fort Bragg, North Carolina

Conditions: Inflammatory Acne Vulgaris
Interventions: Sebacia microparticles and laser, Vehicle suspension and laser, Sebacia microparticles without laser; Device
Lead sponsor: Sebacia, Inc.; Industry
Eligibility: 15 Years to 35 Years
Enrollment: 394 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 19
States / cities: Scottsdale, Arizona • Sacramento, California • Miami, Florida + 15 more

Conditions: Dry Eye Syndromes, Keratoconjunctivitis Sicca
Interventions: KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension; Drug
Lead sponsor: Kala Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 918 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 60
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 53 more

Conditions: Nicotine Dependence
Interventions: GSK598809, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Cancer of Breast, Cancer of the Breast
Interventions: Breast-conserving surgery (BCS), Cavity shave margins (CSM), BREAST-Q Questionnaire, 3-D breast imaging, Indocyanine green, Intraoperative imaging device, Peripheral blood draw; Procedure · Behavioral · Device + 1 more
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 85 Years · Female only
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Chronic Plaque Psoriasis
Interventions: Bimekizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: High Point, North Carolina • Bexley, Ohio

Conditions: Alzheimer's Disease
Interventions: Lecanemab 2.5 mg/kg, Lecanemab 5.0 mg/kg, Lecanemab 10 mg/kg, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 856 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 91
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 70 more

Conditions: Breast Cancer
Interventions: 4-hydroxytamoxifen, breast imaging study, radiomammography; Drug · Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 30 Years to 50 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Schizophrenia
Interventions: Iclepertin, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 611 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 20
States / cities: Bellflower, California • Costa Mesa, California • Long Beach, California + 17 more

Conditions: Acute Ischemic Stroke
Interventions: AB126 Neural Exosomes Intravenous Injection, AB126 Placebo; Biological · Other
Lead sponsor: Aruna Bio, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Houston, Texas

Conditions: Spinal Cord Injuries
Interventions: Living Longer and Stronger with SCI, Control; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Blepharitis
Interventions: Pimecrolimus 0.3% Ophthalmic Ointment, Placebo Ophthalmic Ointment; Drug
Lead sponsor: Famy Life Sciences, a Viatris Company; Industry
Eligibility: 2 Years and older
Enrollment: 477 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 29
States / cities: Pheonix, Arizona • Garden Grove, California • Glendale, California + 26 more

Conditions: Escherichia Infection
Interventions: B7A (ETEC challenge strain), CssBA, dmLT, Placebo; Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Baltimore, Maryland • Cincinnati, Ohio

Conditions: Tumor Hyperinsulinism (Tumor HI)
Interventions: Ersodetug; Drug
Lead sponsor: Rezolute; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 8
States / cities: Chicago, Illinois • Bethesda, Maryland • Boston, Massachusetts + 5 more

Conditions: PTSD
Interventions: Renew; Behavioral
Lead sponsor: Palo Alto Veterans Institute for Research; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Menlo Park, California

Conditions: Nasal Obstruction
Interventions: Vivaer Stylus; Device
Lead sponsor: Aerin Medical; Industry
Eligibility: 22 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 9
States / cities: Fresno, California • Colorado Springs, Colorado • Oradell, New Jersey + 6 more

Conditions: Postoperative Pain
Interventions: Ketamine, Placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetic Retinopathy
Interventions: Octreotide Acetate in Microspheres 20 mg, Octreotide Acetate in Microspheres, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 583 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 1
States / cities: East Hanover, New Jersey

Search by objective public record fields.

Study of Tolerability and Efficacy of BVS857 in Severe Burn Subjects

Communication About Sexual Health in Gynecologic Cancer

Zemplar® Capsule in Reducing Serum Intact Parathyroid Hormone Levels in Chronic Kidney Disease Stage 5 Subjects on Hemodialysis or Peritoneal Dialysis

Geniculate Artery Embolization for Knee Pain Secondary to Osteoarthritis (OA)

RCT of CBT for Insomnia With PLWHA

Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes

Effectiveness and Acceptability of Stellate Ganglion Block for Posttraumatic Stress Disorder Symptoms - Effectiveness

Pivotal Study of Sebacia Microparticles in the Treatment of Acne Vulgaris

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease

Effectiveness of GSK598809, a Selective D3 Antagonist, Added to CBT and NRT for Smoking Cessation and Relapse Prevention

Shave Margins in Breast Conservation Therapy

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis

A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease

Effect of 4-Hydroxytamoxifen Gel on Breast Density, Salivary Sex Steroids, and Quality of Life in Premenopausal Women

Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)

A Phase 1b Study to Assess the Safety and Tolerability of AB126 Neural Exosomes in Patients With Moderate to Severe Acute Ischemic Stroke

Living Longer and Stronger With Spinal Cord Injury (SCI)

A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment

Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults

A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism

Testing a Self-Management App for Symptoms of Posttraumatic Stress

Treatment of Nasal Airway Obstruction Using the Aerin Medical Device

Effect of Postoperative Single Dose of Ketamine on Pain After Mastectomy

Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy